Benchmarking and Change Mechanisms in Personality Disorder Treatment
Launched by KU LEUVEN · Jan 27, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how effective a type of therapy called intensive psychodynamic therapy (PDT) is for treating personality disorders (PDs) in real-life situations, outside of controlled research settings. Researchers want to find out if people experience meaningful improvements in their symptoms and what specific factors help bring about these changes. Since personality disorders can greatly affect a person’s identity and relationships, understanding the effectiveness of treatments in everyday life is crucial.
To participate in this study, individuals must be over 18 years old and have a diagnosed personality disorder confirmed by a psychiatrist through specific assessment tools. Participants should also be comfortable communicating in Dutch. Those with substance abuse issues or acute psychotic symptoms will not be eligible. If you join this study, you can expect to engage in treatment while providing feedback through questionnaires to help researchers learn more about how effective this therapy can be for people like you.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Individuals (male, female, non-binary or other) older than 18 years
- • 2. Meeting criteria for personality disorder as assessed by a psychiatrist and confirmed with the PID-5 and LFPS self-report scales
- • 3. Sufficient mastery of the Dutch language to follow treatment and complete questionnaires
- • 4. Agreeing to participate in the study following informed consent procedure
- Exclusion Criteria:
- • 1. Substance abuse that would interfere with the ability to adhere to the treatment
- • 2. Acute psychotic symptoms as assessed by a psychiatrist
About Ku Leuven
KU Leuven, a prestigious research university located in Belgium, is renowned for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, KU Leuven integrates cutting-edge research with clinical practice, facilitating the development of new therapeutic strategies and medical technologies. The institution's robust infrastructure and expertise in various fields, including biotechnology, pharmacology, and public health, position it as a leader in conducting high-quality clinical research that adheres to rigorous ethical standards and regulatory requirements. Through its clinical trials, KU Leuven aims to contribute significantly to the global biomedical landscape and enhance health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kortenberg, Vlaams Brabant, Belgium
Patients applied
Trial Officials
Celine De Meulemeester, PhD
Principal Investigator
KU Leuven
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported